Asia—Biogen, Eisai’s Alzheimer’s nod; Stemirna’s $188M mRNA vaccine raise; China-made HER2 ADC

Biogen and partner Eisai’s aducanumab have won a landmark—yet widely criticized—FDA approval for Alzheimer’s disease drug Aduhelm, and the companies are eying a big potential market in Asia. China’s Stemirna Therapeutics raised $188 million for its mRNA COVID-19 vaccine ambitions. Chinese authorities have cleared a homegrown HER2-targeted antibody-drug conjugate by RemeGen for stomach cancer. And more. 1. Biogen’s aducanumab crosses FDA […]